

Hypothalamic Obesity (HO) - Pipeline Insight, 2019

<https://marketpublishers.com/r/H25A74E652BEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: H25A74E652BEN

Abstracts

This report can be delivered to the clients within 24 Hours

"Hypothalamic Obesity (HO) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypothalamic Obesity pipeline landscape is provided which includes the disease overview and Hypothalamic Obesity treatment guidelines. The assessment part of the report embraces, in depth Hypothalamic Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypothalamic Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hypothalamic Obesity (HO) Understanding

According to Genetic and Rare Disease Information Centre, Hypothalamic Obesity (HO) is a complex neuroendocrine disorder that is caused by physical or inborn damage to the hypothalamus. Energy balance is regulated by a complex neuroendocrine system and hypothalamus is the main center for energy homeostasis. The mechanical or functional disruption of the hypothalamic network that regulates this system causes intractable weight gain. The pathogenetic mechanisms underlying HO are complex and multifactorial. Weight gain results from damage to the ventromedial hypothalamus, which may lead to hyperphagia, a low resting metabolic rate, autonomic imbalance, growth hormone, gonadotropin, and thyroid-stimulating hormone deficiencies, hypomobility, and insomnia. Disruption of leptin signaling and decreased central sympathetic output seem to have a critical role in the development of HO.

Hypothalamic Obesity Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Hypothalamic Obesity targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Hypothalamic Obesity pipeline report covers 10+ companies. Some of the key players include Saniona (Tesomet), Amylin Pharmaceuticals/Astrazeneca (Exenatide) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Hypothalamic Obesity Analytical Perspective by DelveInsight

In-depth Hypothalamic Obesity Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Hypothalamic Obesity Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Hypothalamic Obesity report provides an overview of therapeutic pipeline activity for Hypothalamic Obesity across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Hypothalamic Obesity therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Hypothalamic Obesity Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hypothalamic Obesity

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Hypothalamic Obesity to formulate effective R&D strategies

Assess challenges and opportunities that influence Hypothalamic Obesity R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Hypothalamic Obesity in licensing and out licensing strategies by identifying prospective partners with progressing projects for Hypothalamic Obesity to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. HYPOTHALAMIC OBESITY (HO)

- 2.1. Hypothalamic Obesity Disease Overview
- 2.2. Hypothalamic Obesity History
- 2.3. Hypothalamic Obesity Symptoms
- 2.4. Hypothalamic Obesity Causes
- 2.5. Hypothalamic Obesity Pathophysiology
- 2.6. Hypothalamic Obesity Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. HYPOTHALAMIC OBESITY (HO) CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. HYPOTHALAMIC OBESITY- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Hypothalamic Obesity companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Hypothalamic Obesity Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Hypothalamic Obesity Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. HYPOTHALAMIC OBESITY PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. HYPOTHALAMIC OBESITY-PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. Tesomet- Saniona
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
 - 6.1.2. Exenatide- Amylin Pharmaceuticals/Astrazeneca
 - 6.1.2.1. Product Description
 - 6.1.2.1.1. Product Overview
 - 6.1.2.1.2. Mechanism of Action
 - 6.1.2.2. Research and Development
 - 6.1.2.2.1. Clinical Studies
 - 6.1.2.2.1.1. Detailed Study Description
 - 6.1.2.2.1.2. Study Results
 - 6.1.2.2.1.3. Clinical Trials: Tabular View
 - 6.1.2.3. Product Development Activities
 - 6.1.2.3.1. Tabulated Product Summary
 - 6.1.2.3.1.1. General Description Table
 - To be continued in the report.....

7. RECENT TECHNOLOGIES

8. HYPOTHALAMIC OBESITY KEY COMPANIES

- 8.1. Amylin Pharmaceuticals
- 8.2. Zafgen/Chong Kun Dang
- 8.3. Saniona
- 8.4. Oramed Pharmaceuticals
- 8.5. Gila Therapeutics
- 8.6. Soleno Therapeutics
- 8.7. Rhythm pharmaceuticals

9. HYPOTHALAMIC OBESITY KEY PRODUCTS

- 9.1. Exenatide
- 9.2. Beloranib
- 9.3. Tesofensine
- 9.4. Leptin
- 9.5. Peptide YY3-36
- 9.6. Diazoxide choline controlled release
- 9.7. Setmelanotide

10. DORMANT AND DISCONTINUED PRODUCTS

- 10.1. Dormant Products
 - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
 - 10.2.1. Reasons for the discontinuation

11. HYPOTHALAMIC OBESITY- UNMET NEEDS

12. HYPOTHALAMIC OBESITY- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

- 14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Hypothalamic Obesity Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Hypothalamic Obesity Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1. Disease Overview

Figure 2. History

Figure 3. Symptoms

Figure 4. Causes

Figure 5. Pathophysiology

Figure 6. Diagnostic Guidelines

Figure 7. Treatment Guidelines

Figure 8. Hypothalamic Obesity companies collaborations, Licensing, Acquisition –Deal Value Trends

Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10. Hypothalamic Obesity Acquisition Analysis

Figure 11. Assessment by Phase of Development

Figure 12. Assessment by Product Type (Mono / Combination)

Figure 13. Assessment by Stage and Product Type

Figure 14. Assessment by Route of Administration

Figure 15. Assessment by Stage and Route of Administration

Figure 16. Assessment by Molecule Type

Figure 17. Assessment by Stage and Molecule Type

Figure 18. Assessment by MOA

Figure 19. Assessment by Stage and MOA

Figure 20. Late Stage Products (Phase-III)

Figure 21. Mid Stage Products (Phase-II)

Figure 22. Early Stage Products (Phase-I)

Figure 23. Pre-clinical and Discovery Stage Products

Figure 24. Inactive Products

Figure 25. Dormant Products

Figure 26. Discontinued Products

Figure 27. Unmet Needs

KEY COMPANIES

Novartis

Amylin Pharmaceuticals

Zafgen/Chong Kun Dang

Saniona

Oramed Pharmaceuticals
Gila Therapeutics
Solenio Therapeutics
Rhythm pharmaceuticals
sanofi

I would like to order

Product name: Hypothalamic Obesity (HO) - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/H25A74E652BEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H25A74E652BEN.html>